Ankündigung • Jun 27
H.U. Group Holdings, Inc. to Report Q1, 2027 Results on Aug 12, 2026 H.U. Group Holdings, Inc. announced that they will report Q1, 2027 results on Aug 12, 2026 Ankündigung • Apr 25
H.U. Group Holdings, Inc. to Report Fiscal Year 2026 Results on May 14, 2026 H.U. Group Holdings, Inc. announced that they will report fiscal year 2026 results on May 14, 2026 Ankündigung • Jan 28
H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 CSF Assay for Research Use Only H.U. Group Holdings Inc. and Fujirebio announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE®? G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer's disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct b-amyloid peptides. CSF pTau217 has emerging as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio's growing portfolio of neurological biomarkers and reinforces the company's leading position in the advancement of associated research tools and diagnostics. The availability of the assay on the fully automated random-access LUMIPULSE G analyzers provides researchers access to convenient, accurate, and robust measurement of pTau 217 in CSF, in addition to blood. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements. Ankündigung • Jan 08
H.U. Group Holdings, Inc. to Report Q3, 2026 Results on Feb 09, 2026 H.U. Group Holdings, Inc. announced that they will report Q3, 2026 results on Feb 09, 2026 Ankündigung • Sep 16
Wakita & Co.,LTD. (TSE:8125) entered into agreement to acquire 80% stake in Care’x Co., Ltd. from H.U. Group Holdings, Inc. (TSE:4544) for ¥5.2 billion. Wakita & Co.,LTD. (TSE:8125) entered into agreement to acquire 80% stake in Care’x Co., Ltd. from H.U. Group Holdings, Inc. (TSE:4544) for ¥5.2 billion on September 16, 2025. A cash consideration of ¥5.2 billion will be paid by Wakita & Co.,LTD. As part of consideration, ¥5.2 billion is paid towards common equity of Care’x Co., Ltd.
For the period ending March 31, 2025, Care’x Co., Ltd. reported total revenue of ¥5.89 billion, EBIT of ¥287 million and net income of ¥244 million. As of March 31, 2025, Care’x Co., Ltd. reported total assets of ¥4.38 billion and total common equity of ¥1.41 billion.
The expected completion of the transaction is November 28, 2025. Ankündigung • Sep 01
H.U. Group Holdings, Inc. to Report Q2, 2026 Results on Nov 11, 2025 H.U. Group Holdings, Inc. announced that they will report Q2, 2026 results on Nov 11, 2025 Ankündigung • Jun 24
H.U. Group Holdings, Inc. to Report Q1, 2026 Results on Aug 08, 2025 H.U. Group Holdings, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025 Ankündigung • Jun 04
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood within just 35 minutes. sTREM2 is a promising biomarker of microglial activation, offering researchers insights into neuroinflammation linked to Alzheimer’s and other neurodegenerative diseases. sTREM2 can be valuable for capturing the dynamics of inflammatory responses or for monitoring inflammatory modulators. This test complements Fujirebio’s growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company’s leading position in advancing neuro biomarker research tools and diagnostics. The new test allows researchers and clinical research professionals to further study and understand the potential clinical utility of this promising microglial biomarker. The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements. Ankündigung • May 16
H.U. Group Holdings, Inc. (TSE:4544) announces an Equity Buyback for 2,500,000 shares, representing 4.4% for ¥5,000 million. H.U. Group Holdings, Inc. (TSE:4544) announces a share repurchase program. Under the program, the company will repurchase up to 2,500,000 shares, representing 4.4% of its issued share capital, for ¥5,000 million. The purpose of the program is to strengthen shareholder returns and position share repurchases as strategic investments in the company. The program will expire on March 31, 2026. As of March 31, 2025, the company had 56,818,397 shares (excluding treasury stock) in issue and 655,425 shares in treasury. Ankündigung • May 15
H.U. Group Holdings, Inc., Annual General Meeting, Jun 17, 2025 H.U. Group Holdings, Inc., Annual General Meeting, Jun 17, 2025. Ankündigung • Mar 25
H.U. Group Holdings, Inc. to Report Fiscal Year 2025 Results on May 15, 2025 H.U. Group Holdings, Inc. announced that they will report fiscal year 2025 results on May 15, 2025 Ankündigung • Dec 06
H.U. Group Holdings, Inc. to Report Q3, 2025 Results on Feb 07, 2025 H.U. Group Holdings, Inc. announced that they will report Q3, 2025 results on Feb 07, 2025 Ankündigung • Sep 03
H.U. Group Holdings, Inc. to Report Q2, 2025 Results on Nov 08, 2024 H.U. Group Holdings, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024 Ankündigung • Jul 26
H.U. Group Holdings, Inc. and Fujirebio Launches the Fully Automated Lumipulse G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. The Research Use Only (RUO) assay is now available in the United States, and it will be available in Japan, Europe and other regions as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. The Lumipulse G GFAP assay will allow the scientific community and clinical research professionals to further study and understand the potential clinical utility of this promising astrocytic biomarker for neurological conditions such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and brain-related acute traumatic injuries or stroke. With the fully automated random-access LUMIPULSE G platform, professionals will be able to measure GFAP in a user-friendly and reliable way. This standardized immunoassay platform is already widely available in labs for routine and research testing of neurological disease-related biomarkers. The new assay meets the necessary quality, throughput, and regulatory requirements to support potential routine testing of GFAP in combination with other tests from the Fujirebio neuro biomarker menu. Ankündigung • Jul 04
H.U. Group Holdings, Inc. to Report Q1, 2025 Results on Aug 08, 2024 H.U. Group Holdings, Inc. announced that they will report Q1, 2025 results on Aug 08, 2024 Ankündigung • May 12
H.U. Group Holdings, Inc., Annual General Meeting, Jun 18, 2024 H.U. Group Holdings, Inc., Annual General Meeting, Jun 18, 2024. Ankündigung • Apr 04
H.U. Group Holdings, Inc. to Report Fiscal Year 2024 Results on May 10, 2024 H.U. Group Holdings, Inc. announced that they will report fiscal year 2024 results on May 10, 2024 Ankündigung • Jan 09
H.U. Group Holdings, Inc. to Report Q3, 2024 Results on Feb 09, 2024 H.U. Group Holdings, Inc. announced that they will report Q3, 2024 results on Feb 09, 2024 Ankündigung • Dec 23
H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 Plasma Assay for the Fully Automated LUMIPULSE G Immunoassay Systems H.U. Group Holdings Inc. and Fujirebio announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems. This CLEIA (chemiluminescent enzyme immunoassay) assay allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human K2EDTA plasma within just 35 minutes. About pTau 217: Current research indicates that plasma pTau, including pTau 217, is a predictor of amyloid status determined either by CSF1 or PET2, and therefore able to differentiate between Alzheimer’s disease (AD) and non-AD neurodegenerative diseases3,4 and to predict progression to AD.5,6 Blood-based biomarkers, such as plasma pTau, could potentially be used as inclusion criteria or to evaluate target engagement and treatment efficacy in clinical trials, and could further advance the development and implementation of disease-modifying treatments in the field of AD and related disorders.7 This assay is designed to measure specifically the phosphorylation on position threonine 217 in human plasma. Ankündigung • Nov 11
H.U. Group Holdings, Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024 H.U. Group Holdings, Inc. revised earnings guidance for the fiscal year ending March 31, 2024. The company now expects net sales of ¥240,000 million against previous guidance of ¥245,000 million; Operating profit of ¥4,000 million against previous guidance of ¥14,000 million; Profit attributable to owners of parent of ¥0 or ¥0.00 per share against previous guidance of ¥6,000 million or ¥105.43 per share. Ankündigung • Sep 19
H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index (USD) H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index (USD) Ankündigung • Sep 02
H.U. Group Holdings, Inc. to Report Q2, 2024 Results on Nov 09, 2023 H.U. Group Holdings, Inc. announced that they will report Q2, 2024 results on Nov 09, 2023 Ankündigung • Jul 06
H.U. Group Holdings, Inc. to Report Q1, 2024 Results on Aug 08, 2023 H.U. Group Holdings, Inc. announced that they will report Q1, 2024 results on Aug 08, 2023 Ankündigung • May 14
H.U. Group Holdings, Inc., Annual General Meeting, Jun 20, 2023 H.U. Group Holdings, Inc., Annual General Meeting, Jun 20, 2023. Ankündigung • Dec 21
H.U. Group Holdings, Inc. to Report Q3, 2023 Results on Feb 08, 2023 H.U. Group Holdings, Inc. announced that they will report Q3, 2023 results on Feb 08, 2023 
